Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
The Korean Journal of Pain
;
: 73-79, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-742182
ABSTRACT
All drugs have both favorable therapeutic and untoward adverse effects. Conventional opioid analgesics possess both analgesia and adverse reactions, such as nausea, vomiting, and respiratory depression. The opioid ligand binds to µ opioid receptor and non-selectively activates two intracellular signaling pathways the G protein pathway induce analgesia, while the β-arrestin pathway is responsible for the opioid-related adverse reactions. An ideal opioid should activate the G protein pathway while deactivating the β-arrestin pathway. Oliceridine (TRV130) has a novel characteristic mechanism on the action of the µ receptor G protein pathway selective (µ-GPS) modulation. Even though adverse reactions (ADRs) are significantly attenuated, while the analgesic effect is augmented, the some residual ADRs persist. Consequently, a G protein biased µ opioid ligand, oliceridine, improves the therapeutic index owing to increased analgesia with decreased adverse events. This review article provides a brief history, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs of oliceridine.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Insuffisance respiratoire
/
Vomissement
/
Pharmacocinétique
/
Biais (épidémiologie)
/
Souris knockout
/
Récepteurs aux opioïdes
/
Récepteur mu
/
Protéines G
/
Protéines et peptides de signalisation intracellulaire
/
Effets secondaires indésirables des médicaments
Limites du sujet:
Animaux
langue:
Anglais
Texte intégral:
The Korean Journal of Pain
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS